Epidiolex-induced skin rash

Epileptic Disord. 2020 Aug 1;22(4):511-514. doi: 10.1684/epd.2020.1189.

Abstract

Epidiolex® (cannabidiol, aka CBD) is a recently approved FDA prescription drug for the treatment of epilepsy associated with Lennox-Gastaut and Dravet syndromes, and is increasingly used for treatment-resistant epilepsy. Rash was rarely reported in Epidiolex® clinical trial data. We report a case of Epidiolex®-related skin rash that developed in a delayed fashion in a 23-year-old female with medically refractory epilepsy. We also review the potential mechanism of Epidiolex®-related skin rash.

Keywords: CBD; Epidiolex; Epidiolex® (cannabidiol); antiepileptics; cannabinoid; drug interaction; hypersensitivity reaction; rash; skin.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Cannabidiol / adverse effects*
  • Cannabinoid Receptor Agonists / adverse effects*
  • Drug Resistant Epilepsy / drug therapy*
  • Exanthema / chemically induced*
  • Female
  • Humans
  • Young Adult

Substances

  • Cannabinoid Receptor Agonists
  • Cannabidiol